<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03158480</url>
  </required_header>
  <id_info>
    <org_study_id>20173357201827</org_study_id>
    <nct_id>NCT03158480</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Immune Therapy for Condyloma</brief_title>
  <official_title>Safety and Efficacy of Immune Therapy for Condyloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenzhen Second People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shenzhen Second People's Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cytokine-induced killer (CIK) cells will be co-cultured with HPV induced dendritic cells
      (DCs); HPV specific DC-CIK will be induced to Condylomata Acuminata patients using
      interferon, whose recurrence rate and total cost will be compared to Condylomata Acuminata
      patients only use interferon.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 25, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Condylomata Acuminata recurrence rate</measure>
    <time_frame>6 months</time_frame>
    <description>Condylomata Acuminata recurrence rate in 6 months after treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>skin tissue HPV gene</measure>
    <time_frame>6 months</time_frame>
    <description>use PCR to testify skin tissue HPV gene</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>side effect</measure>
    <time_frame>6 months</time_frame>
    <description>evaluate and record side effect of each group</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Condylomata Acuminata</condition>
  <arm_group>
    <arm_group_label>DC-CIK+interferon Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dendritic cell-activated cytokine-induced killer cells (DC-CIK) immunotherapy plus interferon intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo+interferon Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>saline as placebo plus interferon intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DC-CIK immunotherapy</intervention_name>
    <description>Cytokine-induced killer (CIK) cells are co-cultured with HPV induced dendritic cells (DCs); HPV specific DC-CIK will be induced to condylomata acuminata patients</description>
    <arm_group_label>DC-CIK+interferon Group</arm_group_label>
    <arm_group_label>Placebo+interferon Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:All patients have typical clinical characters of condyloma, positive for
        HPV-DNA test; All patients have been treated for cryotherapy or laser plus interferon for
        over half a year without completely recovery. All patients or their family will sign
        informed consent and approved by Ethics Committee of Shenzhen Second People's Hospital -

        Exclusion Criteria:pregnant, blood disease, contraindication for immune therapy, allergic
        to interferon
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Shenzhen Second Hospital</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lian Cuihong</last_name>
      <phone>15814692161</phone>
      <email>15814692161@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2017</study_first_submitted>
  <study_first_submitted_qc>May 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2017</study_first_posted>
  <last_update_submitted>June 28, 2017</last_update_submitted>
  <last_update_submitted_qc>June 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DC-CIK</keyword>
  <keyword>interferon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Condylomata Acuminata</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

